Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 08:15 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 25, 2022 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 24, 2022 12:15 ET
|
Phathom Pharmaceuticals
Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of...
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
May 17, 2022 08:01 ET
|
Phathom Pharmaceuticals
New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori (H. pylori)...
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 10, 2022 08:00 ET
|
Phathom Pharmaceuticals
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H....
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 04, 2022 08:01 ET
|
Phathom Pharmaceuticals
Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE)Provides capital for launch of vonoprazan in H. pylori...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
May 03, 2022 17:40 ET
|
Phathom Pharmaceuticals
VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple...
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 01, 2022 08:01 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
March 22, 2022 08:02 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 14, 2022 08:02 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...